Multi‐cohort analysis identifies somatic <i>NTRK</i> mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma-Reference-Cited by-同舟云学术

Multi‐cohort analysis identifies somatic NTRK mutations as a biomarker for immune checkpoint inhibitor use in cutaneous melanoma

Published:2023-11 Issue:11 Volume:13 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Yan Junya¹,Deng Long²,Yu Jiayi³,Wu Xiaowen⁴,Wang Shaoyu⁵,Cang Shundong¹^ORCID

Affiliation:

1. Department of Oncology Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital Zhengzhou China

2. Western Medical Branch of the Chinese PLA General Hospital Beijing China

3. Department of Radiation Oncology Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Peking University Cancer Hospital & Institute Beijing China

4. Department of Renal Cancer and Melanoma Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing) Peking University Cancer Hospital & Institute Beijing China

5. Henan Key Laboratory of Imaging and Intelligent Processing PLA Strategic Support Force Information Engineering University Zhengzhou China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.1478

Reference10 articles.

1. Cancer immunotherapy using checkpoint blockade

2. Immune checkpoint inhibitors in melanoma

3. Targeting TRK family proteins in cancer

4. Trk receptor tyrosine kinases: A bridge between cancer and neural development

5. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability